Biosimilars Advisory Service
Understand Trends and Maximize Opportunities with Updated Insight and Analysis of the Evolving Biosimilars Market
The Biosimilars Advisory Service from BioTrends provides insight and analysis that’s vital to successful business planning in the rapidly evolving biosimilars space.
Quarterly webinars detailing major developments, analyst insight addressing key market changes and therapeutic area-specific primary research and forecasting modules are all included in a subscription to the Biosimilars Advisory Service. Rely on BioTrends to keep you up-to-date on the biosimilars landscape and poised to maximize opportunities for your business.
Features:
Quarterly Industry Webinars—Once per quarter, an hour-long presentation will provide you analysis of the major happenings in biosimilars ranging from legislative and regulatory changes to a snapshot of the competitive landscape.
Customized Event Briefings and Analyst Insight—Understand not only what is happening, but how biosimilars market activity affects your business with customized event briefings and analysis. Our experienced analysts will assess the market impact of an event and give you the information needed to identify challenges and opportunities associated with the evolving biosimilars landscape. As events unfold, a BioTrends analyst will contact you to offer analysis that addresses your greatest concerns and opportunities.
Primary Research and Forecasting Modules- Access primary research and market forecasts to make informed decisions. The Biosimilars Advisory Service covers three therapeutic areas:
- Oncology: granulocyte colony-stimulating factors (G-CSFs) and monoclonal antibodies (mAbs)
- Immunology and Infectious Disease: tumor necrosis factor-alpha (TNF- α) inhibitors and pegylated interferon-alphas (IFNs)
- Endocrinology and Nephrology: Insulins, human growth hormones and erythropoiesis-stimulating agents (ESAs)
Included in the primary research and forecasting modules:
- Payer perspectives – a survey of 40 U.S. pharmacy and medical directors and interviews with European payers, designed to gauge their outlook on biosimilar adoption and probable reimbursement strategies for biosimilars in general, and for specific therapeutic areas.
- Physician landscape – primary research with more than 450 physicians across six specialties (endocrinology, nephrology, gastroenterology/hepatology, rheumatology, solid tumor oncology, hematologic oncology), assessing awareness of and attitudes towards biosimilar use, as well as expected drivers and constraints on biosimilar uptake.
- Market forecast – general market assumptions for biosimilars, plus brand and biosimilar forecasts for more than 26 brands in the U.S., Japan and EU5 (Germany, France, Italy, Spain, UK) markets.
- Webinar – informative online presentation of key findings for each module that provide additional research analysis to help subscribers understand implications and opportunities.
Key Benefits
- Customized event briefings and analyst insight from the BioTrends team following major developments to inform strategic and tactical planning
- Quarterly webinars reviewing substantial regulatory, legislative and corporate biosimilar activities throughout the quarter
- Interactive forecasting tool enabling modified forecasts based on users’ specific business needs
- Primary research on payer and physician attitudes toward biosimilar adoption, reimbursement and market drivers
- Direct access to BioTrends' analysts with extensive industry expertise